Search results for "Pyridine"

showing 10 items of 2516 documents

Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension

2000

To investigate the efficacy and tolerability of lercanidipine, used as monotherapy once a day, in elderly patients with isolated systolic hypertension (ISH), 83 patients were enrolled in this multicenter, double-blind, randomized, placebo-controlled study. All patients were older than 60 years, and their mean age was 66.7 +/- 5.4 years. ISH was defined as SBPor = 160 mmHg, and DBP95 mmHg. After wash-out and placebo run-in periods, patients were randomly assigned to placebo or lercanidipine (10 mg once a day) treatment for 4 weeks. Non-responding patients of the lercanidipine-treated group were later treated with 20 mg of lercanidipine once a day for 4 additional weeks. At the end of the stu…

MaleAgingDihydropyridinesSystoleBlood PressurePlaceboPlacebo groupOrthostatic vital signsDouble-Blind MethodDiastoleHeart ratemedicineHumansAntihypertensive AgentsAgedbusiness.industryLercanidipineMiddle AgedBlood pressureTreatment OutcomeTolerabilityAnesthesiaIsolated systolic hypertensionHypertensionFemaleGeriatrics and Gerontologybusinessmedicine.drug
researchProduct

Behavioral Effects of GABAA Receptor Stimulation and GABA-Transporter Inhibition

2000

Abstract The present analysis addressed behavioral changes after treatment with 4.5 mg/kg or 18.5 mg/kg of the GABA-uptake inhibitor tiagabine combined with either the benzodiazepine diazepam (1.5 mg/kg) or the imidazopyridine zolpidem (0.05 mg/kg), the latter two acting differentially on GABA A receptor subtypes. The study included 97 male PVG/OIaHsd rats. A standard open field, an enriched open field, and an elevated plus-maze was used to study rat behavior. Treatment with the low dose of tiagabine alone induced no specific behavioral effects, whereas the high dose had an anxiolytic-like potential. Furthermore, diazepam but not zolpidem displayed anxiolytic-like effects. Combination of ea…

MaleAgonistGABA Plasma Membrane Transport Proteinsmedicine.medical_specialtyZolpidemTiagabinePyridinesmedicine.drug_classmedicine.medical_treatmentClinical BiochemistryNipecotic AcidsOrganic Anion TransportersMotor ActivityPharmacologyToxicologyBiochemistryOpen fieldBehavioral NeuroscienceInternal medicinemedicineAnimalsHypnotics and SedativesDrug InteractionsNeurotransmitter Uptake InhibitorsTiagabineBiological PsychiatryPharmacologyBenzodiazepineBehavior AnimalChemistryGABAA receptorMembrane ProteinsMembrane Transport ProteinsReceptors GABA-ARatsZolpidemEndocrinologyAnticonvulsantDrug Therapy CombinationCarrier ProteinsDiazepammedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib.

2010

Abstract Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients. Materials and Methods. All patients received 800 mg daily of sorafenib until progression or unacceptable toxicities. We retrospectively analyzed the incidence of rash and hand–foot skin reactions (HFSR) during the first month of treatment, comparing tumor control (partial response …

MaleCancer ResearchPyridinesSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologySkin Toxicity Hepatocellular CarcinomaSorafenib.Aged 80 and overintegumentary systemIncidence (epidemiology)BenzenesulfonatesLiver NeoplasmsMiddle AgedSorafenibRashhumanitiesOncologyHepatocellular carcinomaToxicityDisease ProgressionFemaleDrug Eruptionsmedicine.symptommedicine.drugAdultNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsInternal medicinemedicineCarcinomaHumansneoplasmsSurvival analysisAgedRetrospective StudiesSurrogate endpointbusiness.industryPhenylurea CompoundsExanthemamedicine.diseaseSurvival Analysisdigestive system diseasesSurgerybody regionsMultivariate AnalysisHepatobiliarybusiness
researchProduct

Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.

2014

ABSTRACT:  Aims: To assess the utility of dynamic contrast-enhanced MRI parameters in the demonstration of early antiangiogenic effects and as prognostic biomarkers in second-line treatment of advanced-stage non-small-cell lung cancer with vatalanib. Patients & methods: The transfer constant (Ktrans) and the initial area under the contrast concentration–time curve at 60 s (AUC60) were assessed in 46 patients. Changes were compared with response evaluation from computed tomography imaging and Response Evaluation Criteria In Solid Tumors guidelines. Results: Statistically significant mean reductions in Ktrans (38.4%; p < 0.0001) and AUC60 (24.9%; p < 0.0001) were found at day 2. Af…

MaleCancer Researchmedicine.medical_specialtyVatalanibDrug-Related Side Effects and Adverse ReactionsPyridinesMedizinContrast MediaAngiogenesis InhibitorsStable DiseaseText miningCarcinoma Non-Small-Cell LungmedicineHumansIn patientLung cancerAgedNeoplasm StagingClinical Trials as Topicbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRadiographyOncologyResponse Evaluation Criteria in Solid TumorsDynamic contrast-enhanced MRIDrug EvaluationPhthalazinesFemaleRadiologyNuclear medicinebusinessProgressive diseaseBiomarkersFuture oncology (London, England)
researchProduct

Search for Stroke-Protecting Agents in Endothelin-1-Induced Ischemic Stroke Model in Rats

2012

Background and Objective. Ischemic stroke may initiate a reperfusion injury leading to brain damage cascades where inflammatory mechanisms play a major role. Therefore, the necessity for the novel stroke-protecting agents whose the mechanism of action is focused on their anti-inflammatory potency is still on the agenda for drug designers. Our previous studies demonstrated that cerebrocrast (a 1,4-dihydropyridine derivative) and mildronate (a representative of the aza-butyrobetaine class) possessed considerable anti-inflammatory and neuroprotective properties in different in vitro and in vivo model systems. The present study investigated their stroke-protecting ability in an endothelin-1 (ET…

MaleDihydropyridinesDrug Evaluation PreclinicalInfarctionBrain damagePharmacologyNeuroprotectionIn vivomedicineAnimalsRats WistarStrokeEndothelin-1business.industryGeneral Medicinemedicine.diseaseRatsStrokeDisease Models AnimalNeuroprotective AgentsMechanism of actionendothelin-1; ischemic stroke; neurodegeneration; protection; cerebrocrast; mildronateDrug Therapy Combinationmedicine.symptombusinessReperfusion injuryEx vivoMethylhydrazinesMedicina; Volume 48; Issue 10; Pages: 77
researchProduct

Distinct influence of atypical 1,4-dihydropyridine compounds in azidothymidine-induced neuro- and cardiotoxicity in mice ex vivo.

2008

This study demonstrates the effective protection by compounds of atypical 1,4-dihydropyridine (DHP) series cerebrocrast, glutapyrone and tauropyrone against neuro- and cardiotoxicity caused by the model compound azidothymidine, a well-known mitochondria-compromising anti-HIV drug. In previous in vitro experiments, we have demonstrated distinct effects of these DHP compounds to influence mitochondrial functioning. In the present in vivo experiments, DHP compounds were administered intraperitoneally in mice daily for 2 weeks, per se and in combinations with azidothymidine at doses: azidothymidine 50 mg/kg; cerebrocrast 0.1 mg/kg; glutapyrone 1 mg/kg; and tauropyrone 1 mg/kg. At the end of the…

MaleDihydropyridinesHeart DiseasesRatónAnti-HIV AgentsTaurineApoptosisBiologyPharmacologyToxicologyMiceGlutamatesIn vivomedicineAnimalsPharmacologyCerebral CortexInflammationCardiotoxicityMice Inbred ICRCaspase 3DihydropyridineTranscription Factor RelAGeneral MedicineBiochemistryGene Expression RegulationEnzyme inhibitorApoptosisToxicitybiology.proteinNeurotoxicity SyndromesZidovudineEx vivomedicine.drugBasicclinical pharmacologytoxicology
researchProduct

Computer-guided drug repurposing: Identification of trypanocidal activity of clofazimine, benidipine and saquinavir

2015

In spite of remarkable advances in the knowledge on Trypanosoma cruzi biology, no medications to treat Chagas disease have been approved in the last 40 years and almost 8 million people remain infected. Since the public sector and non-profit organizations play a significant role in the research efforts on Chagas disease, it is important to implement research strategies that promote translation of basic research into the clinical practice. Recent international public-private initiatives address the potential of drug repositioning (i.e. finding second or further medical uses for known-medications) which can substantially improve the success at clinical trials and the innovation in the pharmac…

MaleDihydropyridinesProtein ConformationTrypanosoma cruziProtozoan ProteinsPharmacologyClofazimineDRUG REPOSITIONINGClofazimineMicechemistry.chemical_compoundDrug DiscoverymedicineAnimalsCLOFAZIMINESaquinavirPharmacologybusiness.industryCHAGAS DISEASEOtras Ciencias QuímicasOrganic ChemistrySAQUINAVIRDrug RepositioningCiencias QuímicasGeneral MedicineTrypanocidal AgentsBENIDIPINEMolecular Docking SimulationCysteine EndopeptidasesDrug repositioningchemistryBenidipineFemalebusinessSaquinavirCIENCIAS NATURALES Y EXACTASmedicine.drug
researchProduct

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induct…

2002

Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the d…

MaleDyskinesia Drug-Inducedmedicine.medical_specialtyIndolesCaudate nucleusStriatumIndirect pathway of movementAntiparkinson AgentsLevodopachemistry.chemical_compoundDopamine Uptake InhibitorsParkinsonian DisordersTachykininsInternal medicineNeural PathwaysmedicineAnimalsheterocyclic compoundsRNA MessengerProtein PrecursorsBromocriptineGeneral NeuroscienceMPTPPutamenNeuropeptidesReceptors Purinergic P1CallithrixEnkephalinsMazindoldopamine agonists peptide mRNAs L-DOPA 1-methyl-4-phenyl-1236-tetrahydropyridine primates dyskinesiaBromocriptinenervous system diseasesNeostriatumRopiniroleEndocrinologynervous systemchemistryDyskinesiaSettore BIO/14 - FarmacologiaFemalemedicine.symptommedicine.drugNeuroscience
researchProduct

4-Aminopyridine antagonizes the inhibitory effect of pentobarbital on acetylcholine release in the heart

1980

Effects of pentobarbital on acetylcholine (ACh) release, force of contraction and nervous conduction were studied in isolated heart preparations and in cervical vagus nerves, respectively. 4-Aminopyridine and tetracaine were used as pharmacological tools to eludicate the mode of action of pentobarbital. 1. 4-Aminopyridine (10−4 M) markedly increased the overflow of ACh from the isolated chicken heart evoked by electrical stimulation (1–50 Hz, 1 ms, 40 V) of the cervical vagus nerves. This effect of 4-aminopyridine was highest at low frequencies of stimulation (+ 226% at 1 Hz) and declined with increasing frequencies to reach a minimum augmentation of 22% at 30 Hz. 2. Pentobarbital and tetra…

MaleInotropemedicine.medical_specialtyPentobarbitalContraction (grammar)TetracaineGuinea PigsNeural ConductionAminopyridinesStimulationIn Vitro TechniquesInhibitory postsynaptic potentialTetracaineInternal medicinemedicineAnimalsPentobarbitalPharmacologyChemistryMyocardium4-AminopyridineHeartVagus NerveGeneral MedicineMyocardial ContractionAcetylcholineEndocrinologyDepression ChemicalAnesthesiaFemaleAcetylcholinemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Efficacy of an insecticide paint against insecticide-susceptible and resistant mosquitoes - Part 1: Laboratory evaluation

2010

Abstract Background The main malaria vector Anopheles gambiae and the urban pest nuisance Culex quinquefasciatus are increasingly resistant to pyrethroids in many African countries. There is a need for new products and strategies. Insecticide paint Inesfly 5A IGR™, containing two organophosphates (OPs), chlorpyrifos and diazinon, and insect growth regulator (IGR), pyriproxyfen, was tested under laboratory conditions for 12 months following WHOPES Phase I procedures. Methods Mosquitoes used were laboratory strains of Cx. quinquefasciatus susceptible and resistant to OPs. The paint was applied at two different doses (1 kg/6 m2 and 1 kg/12 m2) on different commonly used surfaces: porous (cemen…

MaleInsecticideslcsh:Arctic medicine. Tropical medicineDiazinonMosquito ControlTime Factorslcsh:RC955-962PyridinesAnopheles gambiaeDrug Resistancelcsh:Infectious and parasitic diseasesToxicologychemistry.chemical_compoundInsect growth regulatorPaintAnimalslcsh:RC109-216biologyResearchbiology.organism_classificationFecunditySurvival AnalysisCulex quinquefasciatusMosquito controlCulexInfectious DiseaseschemistryChlorpyrifosDiazinonParasitologyFemaleChlorpyrifosPyriproxyfen
researchProduct